surmount-1 trial tirzepatide non-diabetic weight loss 🤔Adults with type 2 diabetes and obesity lose less on EVERY GLP-1 drug compared to those without diabetes, consistently ~5% less. Now that we have retatrutide's TRIUMPH-2 data today we can SURMOUNT-1 Trial - Cardionerds Twitter

See what a new study found in the What It Does section of the Protein Supplements Review

Blood or intraerythrocytic parasites like Plasmodium induce oxidative stress by generating ROS in the patients erythrocytes

Acute pancreatitis In January 2026, the UK MHRA has instructed manufacturers to update the product information for all GLP-1 and dual GIP/GLP-1 receptor agonists to highlight the potential risk of severe acute pancreatitis associated with these drugs, including rare reports of necrotizing and fatal pancreatitis [13]

Federal agencies have effectively pulled BPC-157 out of legal circulation, citing the very uncertainties that should give patients and doctors pause

This timing aligns with the medication's mechanism: semaglutide activates GLP-1 receptors in your brainstem and gut, slowing gastric emptying and enhancing satiety signals almost immediately

Zepbound may be covered for obstructive sleep apnea (OSA)